Investing.com -- Replimune Group, Inc. (NASDAQ: REPL) stock plunged 77% after the company announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) ...

Replimune (REPL) stock in focus as the FDA rejects its lead drug RP1 as part of a combination regimen for melanoma, a type of ...

A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at ...

Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.

Replimune (REPL) stock plummeted on Tuesday after the biotechnology company received a Complete Response Letter (CRL) from ...

Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...

Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.

Tesla’s stock tumbled more than 7% on Tuesday, erasing billions in market value from the electric car maker as the rift between CEO Elon Musk and President Donald Trump reignited.

Centene shares plummeted Wednesday after the managed-care company withdrew its full-year outlook after receiving new data about enrollments and rising member health costs. Monitor these major ...

Centene’s stock suffers a historic plunge as underestimation of healthcare costs leads the insurer to withdraw its full-year earnings outlook.

Managed-care specialist Centene withdrew financial guidance for 2025, warning that earnings will fall well short of expectations. Its shares tumbled. Centene's move comes after industry bellwether ...